BRAF and metastatic melanoma: In our cohort of metastatic melanoma patients with baseline serum LDH of ≥2x ULN treated with first-line BRAF(/MEK) inhibitors, median OS was significantly longer in patients with normalized LDH and still responding to initial targeted therapy who started second-line treatment with ICI, compared to those with elevated LDH at start of treatment with ICI.